Twenty years of azithromycin - Sensitivity of major pathogens;Dvadeset godina primjene azitromicina - Osjetljivost najvažnijih uzročnika

Medicus

Volumn 17, Issue 2, 2008, Pages 15-20

  Andrašević, Arjana Tambić ^a  

^a Croatia   (Croatia)

Author keywords

Group A streptococcus; Macrolide resistance; Pneumococcus

Indexed keywords

EID: 70350074462     PISSN: 1330013X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. APPELBAUM PC, BHAMJEE A, SCRAGG JN, HALLETT AF, BOWEN AJ, COOPER RC. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977; 2: 995-997
2. JACOBS MR, KOORNHOF HJ, ROBINS-BROWNE RM i sur. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299: 735-740
3. BOZDOGAN B, APPELBAUM PC. Macrolide resistance in streptococci and Haemophilus influenzae. Clin Lab Med 2004;24:455-475 (Pubitemid 38737261)
4. CHITTUM HS, CHAMPNEY WS. Erythromycin inhibits the assembly of the large ribosomal subunit in growing Escherichia coli cells. Curr Microbiol 1995;30:273-279
5. LECLERCQ R, COURVALIN P. Intrinsic and inusual resistance to macrolide, lincosamide and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother 1991;35:1273-1276
6. ELKINS CA, NIKAIDO H. 3D structure of AcrB: the archetypal multidrug efflux transporter of Escherichia coli likely captures substrates from periplasm. Drug Resist Updat 2003;6:9-13.
7. SIVAPALASINGAM S, STEIGBIGEL NH. Macrolides and clindamycin. U: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 6th ed. Philadelphia: Churchill Livingstone, 2005; 396-417.
8. SHORTRIDGE VD, DOERN GV, BRUEGGEMANN AB, BEYER JM, FLAMM RK. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999 Nov;29(5):1186-1188
9. WEISBLUM B, SIDDHIKOL C, LAI CJ AND DEMOHN V. Erythromycin-inducible resistance in Staphylococcus aureus: requirement for induction. J Bacteriol 1971;106:835-847
10. VERSALOVIC J, SHORTRIDGE D, KIBLER K i sur. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996;40:477-480
11. MEIER A, KIRSCHNER P, SPRINGER B i sur. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994;38:3881-3884
12. GABASHVILI IS, GREGORY ST, VALLE M i sur. The polypeptide tunnel system in the ribosome and its gating in erythromycin resistance mutants of L4 and L22. Mol Cell 2001;8:181-188
13. ROSS JI, EADY EA, COVE JH, CUNLIFFE WJ, BAUMBERG S AND WOOTON JC. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP binding transport super-gene family. Mol Microbiol 1990;4:1207-1214 (Pubitemid 120005382)
14. KLUGMAN KP, LONKS JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg Inf Dis 2005;11:802-807
15. JACOBS MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis 2002;35:565-569
16. PERIC M, BOZDOGAN B, JACOBS MR, APPELBAUM PC. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 2003;47:1017-1022
17. EUCAST Clinical breakpoints 2008. www.escmid.org/research-projects/ eucast/clinical-breakpoints
18. EARSS Annual Report 2007. www.rivm.nl/earss
19. HAUSDORFF WP, BRYANT J, PARADISO PR, SIBER GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000;30:122-140 (Pubitemid 30067070)
20. SIMOR AE, LOUIE M, LOW DE. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network. Antimicrob Agents Chemother 1996;40:2190-2193
21. LOW DE, DE AZAVEDO J, WEISS CA i sur. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002;46:1295-1301
22. DOERN GV, HEILMAN KP, HUYNH HK, RHOMBERG PR, COFFMAN SL, BRUEGGEMANN AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-1729
23. Active Bacterial Core Surveillance (ABCs) Report 2007. www.cdc.gov
24. FELMINGHAM D, FELDMAN C, HRYNIEWITZ W i sur. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect 2002;8:12-42.
25. TAMBIĆ T, TAMBIĆ ANDRAŠEVIĆ A. Rezistencija bakterija na antibiotike u Republici Hrvatskoj u 1998. g. Zagreb: Akademija medicinskih znanosti Hrvatske, 1999.
26. TAMBIĆ T, TAMBIĆ ANDRAŠEVIĆ A. Rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2000. g. Zagreb: Akademija medicinskih znanosti Hrvatske, 2001.
27. TAMBIĆ ANDRAŠEVIĆ A, TAMBIĆ T. Rezistencija bakterijskih izolata u 2007. godini. U: Tambić Andrašević A, Tambić T, ur. Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2007. g. Zagreb: Akademija medicinskih znanosti Hrvatske, 2008:9-96.
28. NAGAI K, APPELBAUM PC, DAVIES TA i sur. Susceptibilities to telithromycin and six other agents and the prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 Central and Eastern European Countries. Antimicrob Agents Chemother 2002; 46: 371-377
29. GUŽVINEC M, TEŠOVIĆ G, TAMBIĆ- ANDRAŠEVIĆ A, ŽIDOVEC-LEPEJ S, TROŠELJ VUKIĆ B, BEGOVAC J. The epidemiology of invasive Streptococcus pneumoniae disease in Croatian children. Med Sci Monit, 2008; 14: PH59-64.
30. TAMBIĆ ANDRAŠEVIĆ A, BAUDOIN T, VUKELIĆ D i sur. ISKRA smjernice za grlobolju: dijagnostički i terapijski pristup - hrvatske nacionalne smjernice. http://iskra.bfm.hr
31. TANZ RR, SHULMAN ST, SHORTRIDGE VD i sur. Macrolide resistance among pediatric pharyngeal Group A streptococci is high in Canada and increasing in the US. International Congress Series 2006;1289:95-98
32. GREEN M, MARTIN JM, KAREN A. BARBADORA i sur. Reemergence of Macrolide Resistance in Pharyngeal Isolates of Group A Streptococci in Southwestern Pennsylvania. Antimicrob Agents Chemother 2004;48:473-476
33. CORNAGLIA G, LIGOZZI M, MAZZARIOL A, VALENTINI M, OREFICI G, FONTANA R. The Italian Surveillance Group for Antimicrobial Resistance, Rapid Increase of Resistance to Erythromycin and Clindamycin in Streptococcus pyogenes in Italy, 1993-1995. Emerg Infect Dis 1996;2 :339-342
34. SEPPALA H, KLAUKKA T, VUOPIO-VARKILA J i sur. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337:441-446
35. Finnish Study Group for Antimicrobial Resistance (FiRe) http://www.ktl.fi/portal/english/projects/fire
36. BINGEN E, BIDET P, MIHAILA-AMROUCHE L i sur. Emergence of Macrolide-Resistant Streptococcus pyogenes Strains in French Children. Antimicrob Agents Chemother 2004;48:3559-3562
37. TAMBIĆ T, TAMBIĆ ANDRAŠEVIĆ A. Rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2000. g. Zagreb: Akademija medicinskih znanosti Hrvatske, 2001.
38. TAMBIĆ T, TAMBIĆ ANDRAŠEVIĆ A. Rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2001. g. Zagreb: Akademija medicinskih znanosti Hrvatske, 2002.
39. NAGAI K, APPELBAUM PC, DAVIES TA i sur. Susceptibility to telithromycin in 1011 Streptococcus pyogenes isolates from 10 Central and Eastern European countries. Antimicrob Agents Chemother 2002; 46: 546-549
40. MALBRUNY B, NAGAI K, COQUEMONT M i sur. Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. J Antimicrob Ther (JAC), 2002;49:935-939 (Pubitemid 34692887)